Archive | Health Professionals

Hunt for Reliable Biomarkers for Immunotherapy Continues in Melanoma

Although immune checkpoint inhibitors have revolutionized the treatment of patients with melanoma, identifying reliable biomarkers of response to this approach has proven to be exceedingly challenging, according to Douglas B. Johnson, MD, MSCI.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model

Since patients with stage I/IIA cutaneous melanoma (CM) are currently not eligible for adjuvant therapies despite relapse risk uncertainty, researchers examined the ability of a recently developed model that combines clinicopathologic and gene expression variables (CP-GEP) to identify patients with stage I/IIA melanoma who have a high risk for disease relapse.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Personalized Treatments, Overcoming Resistance Is Needed in Melanoma

With an estimated 5-year survival rate of 50% and an ongoing issue of resistance, Georgina Long, AO, BSc, PhD, MBBS, FRACPP, FAHMS, said that the next steps with immunotherapy in melanoma will focus on stratifying patients, personalizing therapy, and refining localized regimens.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Phase 2 Study Finds Nivolumab-Ipilimumab Combo Shows Activity in Metastatic Uveal Melanoma

A single-arm phase 2 study published in the Journal of Clinical Oncology found that the combination regimen of nivolumab (Opdivo) plus ipilimumab (Yervoy) demonstrates activity in metastatic uveal melanoma, with deep and sustained confirmed responses.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials